Biotech Values

[DewDiligence]

GTCB – U.S. ATryn timeline (updated):

1Q07: Complete patient enrollment
3Q07: Submit BLA
3Q08: Potential product launch

The above assumes a standard ten-month FDA review. A six-month priority review is possible, but a determination on this will not be made by the FDA until the BLA is submitted.